Links
		The following websites may provide relevant sources of rheumatology news and information. Note: The websites listed below are the property and copyright of their respective owners. KineretRx.com is not responsible for and does not endorse the content on these sites and only link to these resources as a courtesy. American College of Rheumatology The official website of the American College of Rheumatology. Designed for specialists in arthritis care and research. Arthritis National Research Foundation The official website of the Arthritis National Research Foundation. Includes the latest research, grant awards, and proposal guidelines. National Institute of Arthritis The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) website. Bibliographies, scientific research databases, fact sheets, brochures, results of clinical trials, and more. Annals of Rheumatic Diseases The online version of the Annals of Rheumatic Diseases. Extended reports, reviews, abstracts, and letters. Johns Hopkins Arthritis Center Educational resource for health care professionals addressing the disease processes that cause arthritis and their treatments. Journal of Clinical Rheumatology Original articles, case reports, reviews, brief reports, expert commentary, letters to the editor, and more. International League of Associations for Rheumatology Worldwide organization devoted to all aspects of rheumatology and rheumatic disorders. European League Against Rheumatism (EULAR) Website supporting EULAR's goal to promote, stimulate, and support the research, prevention, treatment, and rehabilitation of rheumatic diseases. The Bone and Joint Decade: 2000–2010 A United Nations-sponsored initiative to raise awareness about bone and joint disorders. The Arthritis Foundation The Arthritis Foundation website supporting its treatment research and goals of improving the quality of life for those affected by arthritis. RheumatologyWeb.com Provides updates on new clinical developments. Includes evaluations of new research, opinions on issues of concern, and resources for practicing physicians faced with challenging cases.   ABOUT KINERET® ABOUT IL-1 PROFESSIONAL RESOURCES REIMBURSEMENT IMPORTANT PRODUCT SAFETY INFORMATION GLOSSARY
	Kineret® (anakinra) is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease-modifying antirheumatic drugs (DMARDs). Kineret® can be used alone or in combination with DMARDs other than tumor necrosis factor (TNF) blocking agents. In clinical trials, there was a risk of serious infections (2% in Kineret® patients vs. less than 1% in placebo patients). Kineret® should be discontinued if a patient develops an infection, however most patients can continue taking Kineret® after their infection resolves. Kineret® should not be used with TNF-blocking agents such as etanercept, adalimumab, and infliximab. A 7% rate of serious infections was observed in a 24-week study of concurrent administration of Kineret® and etanercept. Kineret® is contraindicated in patients with known hypersensitivity to E coli-derived proteins, Kineret®, or any components of the product. The most common side effect in clinical trials was injection site reaction, which was usually mild and characterized by redness, swelling, and pain. Amgen.com | Site Map © 2008 Amgen. All rights reserved. This site is intended for U.S. health care professionals only.